Structure-activity relationships among desazadesferrithiocin analogues

Advances in Experimental Medicine and Biology

Volumn 509, Issue , 2003, Pages 167-184

  Bergeron, Raymond J ^a   Wiegand, Jan ^a   McManis, James S ^a   Weimar, William R ^a   Huang, Guangfei ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; DEFERRIFERRITHIOCIN; DESAZADESFERRITHIOCIN DERIVATIVE; ENTEROCHELIN; IRON CHELATING AGENT; LIGAND; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; PENTETIC ACID; RHODOTORULIC ACID; SIDEROPHORE; UNCLASSIFIED DRUG; VIBRIOBACTIN; DIHYDROPYRIDINE DERIVATIVE; IRON; THIAZOLE DERIVATIVE;

CHEMICAL REACTION; DRUG DESIGN; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; IRON CHELATION; NEPHROTOXICITY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY; STREPTOMYCES ANTIBIOTICUS; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; HUMAN; IRON OVERLOAD; METABOLISM;

STREPTOMYCES; STREPTOMYCES ANTIBIOTICUS;

ANIMALS; DIHYDROPYRIDINES; DRUG DESIGN; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIGANDS; SIDEROPHORES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 0042309610     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (57)

1. Ortiz de Montellano PR ed Cytochrome p450 - structure, metabolism, and biochemistry. New York: Plenum; 1986.
2. Sahlin M, Petersson L, Graslund A, et al. Magnetic interaction between the tyrosyl free radical and the antiferromagnetically coupled iron center in ribonucleotide reductase. Biochemistry 1987;26:5541-5548.
3. Raymond KN, Carrano CJ. Coordination chemistry and microbial iron transport. Acc Chem Res 1979;12:183-190.
4. Halliwell B. Iron, oxidative damage, and chelating agents. Bergeron RJ, Brittenham GM, eds. The development of iron chelators for clinical use. Boca Raton, CRC, 1994,33-56.
5. Britigan BE, Pou S, Rosen GM, Lilleg DM, Buettner GR. Hydroxyl radical is not a product of the reaction of xanthine oxidase and xanthine. The confounding problem of adventitious iron bound to xanthine oxidase. J Biol Chem 1990;265:17533-17538.
6. Bergeron RJ. Iron: A controlling nutrient in proliferative processes. Trends Biochem Sci 1986;11:133-136.
7. Bickel H, Hall GE, Keller-Schierlein W, et al. Metabolic products of actinomycetes. XXVII. Constitutional formula of ferrioxamine B. Helv Chim Acta 1960;43:2129-2138.
8. Bickel H, Bosshardt R, Gäumann E, et al. Metabolic products of actinomycetes. XXVI. Isolation and properties of ferrioxamines A to F, representing new sideramine compounds. Helv Chim Acta 1960;43:2118-2128.
9. Kunze B, Trowitzsch-Kienast W, Höfle G, Reichenbach H. Nannochelins A, B, and C, new iron-chelating compounds from Nannocyslis exedens (myxobacteria). J Antibiot 1992;45:147-150.
10. Atkin CL, Neilands JB. Rhodotorulic acid, a diketopiperazine dihydroxamic acid with growth-factor activity. I. Isolation and characterization. Biochemistry 1968;7:3734-3739.
11. Tait GH. The identification and biosynthesis of siderochromes formed by Micrococcus denitrificans. Biochem J 1975;146:191-204.
12. Peterson T, Neilands JB. Revised structure of a catecholamide spermidine siderophore from Paracoccus denitrificans. Tetrahedron Lett 1979:4805-4808.
13. Griffiths GL, Sigel SP, Payne SM, Neilands JB. Vibriobactin, a siderophore from Vibrio cholerae. J Biol Chem 1984; 259:383-385.
14. Martell AE, Motekaitis RJ, Sun Y, Clarke ET. Ligand design of chelating agents effective in the coordination of Fe(III) and for the removal of iron in cases of iron overload. Bergeron RJ, Brittenham GM, eds. The development of iron chelators for clinical use. Boca Raton, CRC, 1994,329-351.
15. Anderegg G, L'Eplattenier F, Schwarzenbach G. Hydroxamate complexes. II. Application of the pH method. Helv Chim Acta 1963;46:1400-1408.
16. Harris WR, Carrano CJ, Cooper SR, et al. Coordination chemistry of microbial iron transport compounds. XIX. Stability constants and electrochemical behavior of ferric enterobactin and model complexes. J Am Chem Soc 1979;101:6097-6104.
17. Motekaitis RJ, Martell AE. Stabilities of the iron(III) chelates of 1,2-dimethyl-3-hydroxy-4-pyridinone and related ligands. Inorg Chim Acta 1991;183:71-80.
18. Clarke ET, Martell AE. Stabilities of 1,2-dimethyl-3-hydroxy-4- pyridinone chelates of divalent and trivalent metal ions. Inorg Chim Acta 1992;191:56-63.
19. Neilands JB, Peterson T, Leong SA. High affinity iron transport in microorganisms. Iron (III) coordination compounds of the siderophores agrobactin and parabactin. Martell AE, ed. Inorganic chemistry in biology and medicine. Vol. 140. American Chemical Society symposia. Washington, D.C., American Chemical Society, 1980,263-278.
20. Harris WR, Carrano CJ, Raymond KN. Spectrophotometric determination of the proton-dependent stability constant of ferric enterobactin. J Am Chem Soc 1979;101:2213-2214.
21. Avdeef A, Sofen SR, Bregante TL, Raymond KN. Coordination chemistry of microbial iron transport compounds. 9. Stability constants for catechol models of enterobactin. J Am Chem Soc 1978;100:5362-5370.
22. Anderegg G, Räber M. Metal complex formation of a new siderophore desferrithiocin and of three related ligands. J Chem Soc, Chem Commun 1990:1194-1196.
23. Hahn FE, McMurry TJ, Hugi A, Raymond KN. Coordination chemistry of microbial iron transport. 42. Structural and spectroscopic characterization of diastereomeric Cr(III) and Co(III) complexes of desferriferrithiocin. J Am Chem Soc 1990;112:1854-1860.
24. L'Eplattenier F, Murase I, Martell AE. New multidentate ligands. VI. Chelating tendencies of N,N-di(2-hydroxybenzyl)ethylenediamine-N,N′- diacetic acid. J Am Chem Soc 1967;89:837-843.
25. Pitt CG, Gupta G, Estes WE, et al. The selection and evaluation of new chelating agents for the treatment of iron overload. J Pharmacol Exp Ther 1979;208:12-18.
26. Kontoghiorghes GJ, Sheppard L, Chambers S. New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones. Arzneimittelforschung 1987;37:1099-1102.
27. Bergeron RJ, Liu Z-R, McManis JS, Wiegand J. Structural alterations in desferrioxamine compatible with iron clearance in animals. J Med Chem 1992;35:4739-4744.
28. Harris WH, Raymond KN. Ferric ion sequestering agents. 3. The Spectrophotometric and potentiometric evaluation of two new enterobactin analogs: 1,5,9-N,N′,N″-tris(2,3-dihydroxybenzoyl) cyclotriazatridecane and 1,3,5-N,N′,N″-tris(2,3-dihydroxybenzoyl) triaminomethylbenzene. J Am Chem Soc 1979;101:6534-6541.
29. Motekaitis RJ, Sun Y, Martell AE. N,N′-bis(pyridoxyl) ethylenediamine-N,N′-diacetic acid (PLED) and N,N′-bis(2-hydroxy-5- sulfobenzyl)ethylenediamine-N,N′-diacetic acid (SHBED). Inorg Chim Acta 1989;159:29-39.
30. Fahey JL, Rath CE, Princiotto JV, Brick IB, Rubin M. Evaluation of trisodium calcium diethylenetriaminepentaacetate in iron storage disease. J Lab Clin Med 1961;57:436-449.
31. Smith RS. Iron excretion in thalassemia major after administration of chelating agents. Br Med J 1962;2:1577-1580.
32. Wöhler F. The treatment of haemochromatosis with desferrioxamine. Acta Haematol 1963;30:65-87.
33. Pippard MJ, Jackson MJ, Hoffman K, Petrou M, Modell CB. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scand J Haematol 1986;36:466-472.
34. Wonke B, Hoffbrand AV, Aldouri M, et al. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA. Arch Dis Child 1989;64:77-82.
35. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
36. Pippard MJ. Desferrioxamine-induced iron excretion in humans. Bailleres Clin Haematol 1989;2:323-343.
37. Whitten CF, Gibson GW, Good MH, Goodwin JF, Brough AJ. Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: Clinical observations, experimental studies, and theoretical considerations. Pediatrics 1965;36:322-335.
38. Athanasiou A, Shepp MA, Necheles TF. Anaphylactic reaction to desferrioxamine. Lancet 1977;2:616.
39. Shalit M, Tedeschi A, Miadonna A, Levi-Schaffer F. Desferal (desferrioxamine) - a novel activator of tissue-type mast cells. J Allergy Clin Immunol 1991;88:854-860.
40. Bousquet J, Navarro M, Robert G, Aye P, Michel FB. Rapid desensitization for desferrioxamine anaphylactoid reactions. Lancet 1983;2:859-860.
41. Miller KB, Rosenwasser LJ, Besserte JAM, Beer DJ, Rocklin RE. Rapid desensitisation for desferrioxamine anaphylactic reaction. Lancet 1981;1:1059.
42. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986;314:869-873.
43. Nouel O, Voisin PM, Vaucel J, Dartois Hoguin M, Le Bris M. [Yersinia enterocolitica septicemia associated with idiopathic hemochromatosis and deferoxamine therapy. A case]. Presse Med 1991;20:1494-1496.
44. Bentur Y, McGuigan M, Koren G. Deferoxamine (desferrioxamine). New toxicities for an old drug. Drug Saf 1991;6:37-46.
45. Naegeli H-U, Zähner H. Metabolites of microorganisms. Part 193. Ferrithiocin. Helv Chim Acta 1980;63:1400-1406.
46. Bergeron RJ, Wiegand J, Dionis JB, et al. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators. J Med Chem 1991;34:2072-2078.
47. Bergeron RJ, Streiff RR, Wiegand J, et al. A comparative evaluation of iron clearance models. Ann N Y Acad Sci 1990;612:378-393.
48. Bergeron RJ, Streiff RR, Creary EA, et al. A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. Blood 1993;81:2166-2173.
49. Bergeron RJ, Liu CZ, McManis JS, et al. The desferrithiocin pharmacophore. J Med Chem 1994;37:1411-1417.
50. Bergeron RJ, Wiegand J, Wollenweber M, et al. Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators. J Med Chem 1996;39:1575-1581.
51. Bergeron RJ, Wiegand J, Weimar WR, et al. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators. J Med Chem 1999;42:95-108.
52. Bergeron RJ, Wiegand J, McManis JS, et al. Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues. J Med Chem 1999;42:2432-2440.
53. Bergeron RJ, Weimar WR, Wiegand J. Pharmacokinetics of orally administered desferrithiocin analogs in Cebus apella primates. Drug Metab Dispos 1999;27:1496-1498.
54. Brittenham GM. Pyridoxal isonicotinoyl hydrazone (PIH): Effective iron chelation after oral administration. Ann N Y Acad Sci 1990:612:315-326.
55. Shetty B, Badr M, Melethil S. Evaluation of hepatic metabolism of salicylic acid in perfused rat liver. J Pharm Sci 1994;83:607-608.
56. McMahon TF, Stefanski SA, Wilson RE, et al. Comparative acute nephrotoxicity of salicylic acid, 2,3-dihydroxybenzoic acid, and 2,5-dihydroxybenzoic acid in young and aged Fischer 344 rats. Toxicology 1991;66:297-311.
57. Bergeron RJ, Wiegand J, Ratliff-Thompson K, Weimar WR. The origin of the differences in (R)-and (S)-desmethyldesferrithiocin: Iron-clearing properties. Ann N YAcad Sci 1998;850:202-216.